Jih-Heng Li

Title: The Innovative Contributions of Jih-Heng Li

Introduction: Jih-Heng Li is a notable inventor based in Taipei, Taiwan. He has made significant strides in the field of cancer research through his innovative patent. His work focuses on developing methods to inhibit the growth of cancer cells, particularly in the urinary system.

Latest Patents: Jih-Heng Li holds a patent for a preparation method of a supercritical extract derived from the dried stem of a specific material. This extract is obtained by pulverizing the material into particles and using supercritical carbon dioxide fluid for extraction. The active ingredient, subamolide A, has shown potential in inhibiting the growth of human urothelial carcinoma cell lines. Furthermore, subamolide A can synergistically enhance the effects of cisplatin (CDDP) or gemcitabine (Gem) in treating cancers related to the urinary system. This innovation positions subamolide A as a promising candidate for anticancer drug development.

Career Highlights: Jih-Heng Li is affiliated with Kaohsiung Medical University, where he continues to contribute to research and development in the medical field. His dedication to advancing cancer treatment through innovative methods has garnered attention in the scientific community.

Collaborations: Jih-Heng Li collaborates with esteemed colleagues, including A-Mei Huang and Chung-Yi Chen. Their combined expertise enhances the research efforts and contributes to the advancement of cancer therapies.

Conclusion: Jih-Heng Li's innovative work in cancer research exemplifies the impact of scientific advancements on healthcare. His patent for a supercritical extract demonstrates the potential for new treatments in combating cancer. The contributions of inventors like Jih-Heng Li are vital for the ongoing fight against diseases and improving patient outcomes.